Fresh data backs Amplia push against pancreatic, ovarian cancer
Amplia Therapeutics' lead drug narmafotinib showed promising results against pancreatic cancer in laboratory studies led by Sydney's Garvan Institute, targeting tumor fibrosis and chemotherapy resistance. The focal adhesion kinase inhibitor demonstrated reduced tumor spread and enhanced anti-tumor activity when combined with chemotherapy.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 31 Jul 2026, 03:15 UTC · Updated 31 Jul 2026, 03:30 UTC
Summary by OZbrief Editorial. Original report: SMH. Editorial policy · Corrections
Trending
- The five-star Melbourne luxury hotel that sits dusty and abandoned
- Kyle Sandilands launches $99 annual streaming service with daily four-hour shows
- ‘Not my signature’: Anytime Fitness probes false signatures on contracts
- As easy as ABC: Inside Victoria’s crime maze
- NSW minister reports 'vile' online threats to police
- Screening missed bus driver's opioid use before deadly wedding crash